ReviewDiscover oncology2025
Therapeutic potential of metformin-based combination therapy in acute myeloid leukemia.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute myeloid leukemia (AML) is the most prevalent form of acute leukemia. Despite great efforts, the overall prognosis for patients with AML remains poor, and the mortality rate due to relapse is also considerable. Consequently, the disease poses treatment challenges. Several studies have indicated that metformin may serve as a beneficial adjunct to traditional anti-leukemia medications, especially enhancing their effectiveness against drug resistance; however, it is not effective when used as a standalone treatment. In this context, combination therapies are currently being explored as a promising treatment option.
methodsThis study is a narrative review. A comprehensive literature search across multiple databases, including PubMed, Google Scholar, Scopus, Embase and Cochrane, yielded 103 relevant articles up to July 2024. From an initial total of 103 articles, we excluded unrelated and duplicate articles, as well as those for which the full text was unavailable and review articles. Ultimately, 32 articles were included in the study. During the database search, we employed search terms such as AML, combination, and metformin to find relevant articles.
resultsAccording to the results of the studies, the combination of metformin with gilteritinib, sorafenib, 6-benzylthionosine, venetoclax, diclofenac, diflunisal, and cytarabine reduces intracellular ATP levels, inhibits glycolysis, halts the cell cycle, diminishes oxidative phosphorylation, increases the expression of anti-apoptotic proteins and increases cytotoxicity. This combination also induces apoptosis, reduces cell growth, and ultimately leads to a significant decrease in the burden of AML and an increase in overall survival for these patients.
conclusionsTherefore, combining these drugs with metformin may enhance the synergistic effect and improve the treatment of AML patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.